IRCT20111206008307N42CompletedPhase 3
Empagliflozin effects in patients with ST-elevation myocardial infarction undergoing primary PCI: a randomized clinical trial
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Enrollment
- 100
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to 80 years (—)
- Sex
- All
Inclusion Criteria
- •Patients with STEMI undergoing primary PCI
- •Patients aged between 18 to 80 years
- •Consented patients
Exclusion Criteria
- •Renal failure (eGFR < 30)
- •Hepatic failure
- •Systolic blood pressure less than 100 mmHg
- •Inflammatory and autoimmune diseases
- •Diabetes mellitus
- •Chronic heart failure
- •Psychiatric disorders
- •Empagliflozin contraindications
- •History of receiving empagliflozin
- •History of myocardial infarction
- •Arrival more than 6 hours from symptoms onset
Investigators
Similar Trials
Not yet recruiting
Not Applicable
Clinical effects of empagliflozin dose increase in patients with type 2 diabetes: a retrospective observational studyType 2 diabetesJPRN-UMIN000041543Department of Metabolic Medicine, Nishinihon Hospital100
Completed
Phase 3
Dapagliflozin effects in patients with myocardial infarctioMyocardial infarction.ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarctionIRCT20111206008307N44Tabriz University of Medical Sciences100
Active, not recruiting
Phase 1
SGLT2 inhibition with empagliflozin in patients with type 2 diabetes mellitus: Influences on left ventricular mass, function, and lipid content of myocardium (EMPATROPHY)Patients with type 2 diabetes mellitus on background metformin treatment.MedDRA version: 18.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2014-003313-28-DEHannover Medical School60
Completed
Phase 1
Empagliflozin in non alcoholic fatty liverDiabetic patient with non alcoholic fatty liver.Other specified inflammatory liver diseasesK75.8IRCT20150706023084N18Islamic Azad University30
Not yet recruiting
Phase 2
Assessment of extra-renal effects of SGLT2-inhibitors in anuric haemodialysis patients using microneurographyEnd Stage Kidney Disease (ESKD) with AnuriaRenal and Urogenital - Kidney diseaseACTRN12623001237673Dobney Hypertension Centre20